PRMT inhibitors, particularly those targeting PRMT1 and PRMT5 due to their well-documented role in cancer progression, are being investigated as therapies for hematological malignancies and solid tumors and have progressed to clinical trials [199,200,201] (Table 3). The gene discussed is PRMT5; the disease is cancer.